| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 0.55 | 0.00 (0.00%) | 0.3418 - 0.90 | 0.0 |
Market data as of 12:00AM 01/30/13. Quotes are delayed by at least 15 min.
| Open | -- |
|---|---|
| Previous Close | 0.55 |
| Day's Range | -- - -- |
| Market Cap | 20.5M |
| Avg Volume (10 Day) | 0.0 |
| Price/Earnings (Trailing 12 Mo.) | 0.7x |
| Earnings Per Share (Trailing 12 Mo.) | 0.78 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Pass |
| Have investors caught on? | Pass |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
China Botanic Pharmaceutical Inc. Announces Receipt of Delisting Notice
PR Newswire - Tuesday 05/07/2013 9:00 AM ET
| CBP | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 20.56% | |
| Net Income Growth (1yr) | 9.94% | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | 142.86% | |
| Price/Sales | 0.24 |
| Company | Last | Change |
|---|---|---|
| Strategic Diagnostics Inc | 1.01 | 0.00% |
| Merus Labs International Inc | 0.68 | +12.68% |
| Ibio Inc | 0.43 | +13.64% |
| DARA BioSciences Inc | 0.73 | +2.66% |
| Reliv International Inc | 1.31 | -0.01% |
Data is delayed by at least 15 min.